Antagonism between Gefitinib and Cisplatin in Non-small Cell Lung Cancer Cells: Why Randomized Trials Failed?

Introduction: Four phase III randomized trials adding epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors to standard chemotherapeutics in patients with advanced non-small cell lung cancer (NSCLC) have failed to show benefits. The mechanism of these failures was examined. Methods: Fifteen previously untreated NSCLC cell lines were simultaneously treated with gefitinib plus cisplatin. Three exhibited sensitizing-EGFR mutations. Three selected lines were further tested with paclitaxel/cisplatin, paclitaxel/gefitinib, and paclitaxel/cisplatin/gefitinib combinations. The tetrazolium colorimetric assay with application of the classic isobole method was used, and dose-versus-log-response curves (DRCs) were analyzed to evaluate possible resistance mechanisms. Results: Of the 15 cell lines tested, combined gefitinib/cisplatin was significantly antagonistic in 10 wild-type and three sensitizing-EGFR mutant cell lines (group mean combination index = 1.184, 95% confidence interval = 1.12–1.24, p = 0.001). The mean combination index values of paclitaxel/cisplatin/gefitinib were higher than or comparable with those of paclitaxel/cisplatin and paclitaxel/gefitinib. DRC analysis consistently showed nonsaturable passive resistance, suggesting that gefitinib at 0.001 to 0.3 &mgr;M can interfere with cisplatin cell entry (at concentrations >1–3 &mgr;M) in a dose-dependent manner and lead to antagonism. This antagonism may or may not be schedule dependent in different cell lines. Conclusions: In most EGFR wild-type or sensitizing-mutant NSCLC cells, the concomitant gefitinib/cisplatin combination showed antagonism, likely because gefitinib interfered with cisplatin entry into the cell. The findings that three-drug combination was not better than the two-drug combinations are in accordance with the results of the randomized trials. The EGFR-tyrosine kinase inhibitor/platinum antagonism is a possible reason for the failure of those randomized trials.

[1]  D. Stewart.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. , 2010, Critical reviews in oncology/hematology.

[2]  K. Kelly,et al.  Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  W. Pao,et al.  Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Leyland-Jones,et al.  EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality , 2008, British Journal of Cancer.

[5]  D. Hayes,et al.  Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  M. Gottesman,et al.  The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. , 2008, Annual review of pharmacology and toxicology.

[7]  M. Meyerson,et al.  PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. , 2007, Cancer research.

[8]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[9]  O. Olopade,et al.  Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  L. Kèlland,et al.  The resurgence of platinum-based cancer chemotherapy , 2007, Nature Reviews Cancer.

[11]  D. Stewart,et al.  Mechanisms of resistance to cisplatin and carboplatin. , 2007, Critical reviews in oncology/hematology.

[12]  J. Milanowski,et al.  Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Pao,et al.  Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[14]  D. Gandara,et al.  Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. , 2006, Clinical lung cancer.

[15]  A. Ashworth,et al.  Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment , 2006, Molecular Cancer Therapeutics.

[16]  David J. Chen,et al.  Radiation-induced Epidermal Growth Factor Receptor Nuclear Import Is Linked to Activation of DNA-dependent Protein Kinase* , 2005, Journal of Biological Chemistry.

[17]  D. Gandara,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  T. Chou,et al.  Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[21]  N. Normanno.  Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. Hochhauser,et al.  Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) , 2004, Clinical Cancer Research.

[23]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Socinski.  Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[25]  G. Giaccone.  The Role of Gefitinib in Lung Cancer Treatment , 2004, Clinical Cancer Research.

[26]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[27]  B. Higgins,et al.  Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models , 2004, Anti-cancer drugs.

[28]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[29]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Baselga.  Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Paradiso,et al.  The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines , 2003, Cancer Chemotherapy and Pharmacology.

[33]  A. Harris,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  P. Bunn,et al.  ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. , 2002, Seminars in oncology.

[35]  W. Denny,et al.  Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033 , 2001, Anti-cancer drugs.

[36]  E K Rowinsky,et al.  Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Kris,et al.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  C. Arteaga,et al.  Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. , 1997, Journal of the National Cancer Institute.

[40]  Kuo‐Ting Chang,et al.  Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. , 1996, Cancer research.

[41]  B. Kramer,et al.  Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines. , 1993, Cancer research.

[42]  J. Minna,et al.  Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. , 1991, Oncogene.

[43]  B. Kramer,et al.  Schedule‐dependent in vitro combination effects of methotrexate and 5‐fluorouracil in human tumor cell lines , 1991, International journal of cancer.

[44]  C. Macleod,et al.  Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. , 1990, The Journal of clinical investigation.

[45]  M C Berenbaum,et al.  Synergy, additivism and antagonism in immunosuppression. A critical review. , 1977, Clinical and experimental immunology.

[46]  C. Chiu,et al.  Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. , 2005, Lung cancer.

[47]  G. Raaphorst,et al.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis , 2004, Investigational New Drugs.

[48]  G. Giaccone,et al.  Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. , 1992, Journal of the National Cancer Institute. Monographs.

[49]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.